Publications by authors named "Mark Surber"

Claim this Profile
H
Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Gali Epstein Shochet, Becky Bardenstein-Wald, Mary McElroy, Andrew Kukuy, Mark Surber

Int J Mol Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galectin-3 levels are elevated following nintedanib treatment.
Gali Epstein Shochet, Alon Pomerantz, David Shitrit, Becky Bardenstein-Wald, Kjetil Ask, Mark Surber

Ther Adv Chronic Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship.
Gali Epstein-Shochet, Stephen Pham, Steven Beck, Safaa Naiel, Olivia Mekhael, Mark W Surber

Pulm Pharmacol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis.
Mark W Surber, Steve Beck, Stephen Pham, Angela T Marsden, Senthil K Gandi

Pulm Pharmacol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Jun Keng Khoo, A Bruce Montgomery, Kelly L Otto, Mark Surber, Jessica Faggian

J Aerosol Med Pulm Drug Deliv· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis.
Lisa M Kaminskas, Cornelia B Landersdorfer, Robert J Bischof, Nathania Leong, Jibriil Ibrahim, Mark W Surber

Pharm Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical industry, academia and patient advocacy organizations: what is the recipe for synergic (win-win-win) collaborations?
Daniel M Rose, Richard Marshall, Mark W Surber

Respirology· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction.
Bakytbek Egemnazarov, Ralph T Schermuly, Bhola K Dahal, Garry T Elliott, Niel C Hoglen, Mark W Surber

Respir Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of bacterial minicells to transfer plasmid DNA to eukaryotic cells.
Matthew J Giacalone, Angela M Gentile, Brian T Lovitt, Tong Xu, Mark W Surber

Cell Microbiol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery.
Matthew J Giacalone, Roger A Sabbadini, Amy L Chambers, Sabitha Pillai, Neil L Berkley, Mark W Surber

Vaccine· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxic protein expression in Escherichia coli using a rhamnose-based tightly regulated and tunable promoter system.
Matthew J Giacalone, Angela M Gentile, Brian T Lovitt, Neil L Berkley, Carl W Gunderson, Mark W Surber

Biotechniques· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis